Significance of GSTP1 for predicting the prognosis and chemotherapeutic efficacy in esophageal squamous cell carcinoma

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1687-1694

  Yamamoto, Yusuke ^a   Konishi, Hirotaka ^a   Ichikawa, Daisuke ^a   Arita, Tomohiro ^a   Shoda, Katsutoshi ^a   Komatsu, Shuhei ^a   Shiozaki, Atsushi ^a   Ikoma, Hisashi ^a   Fujiwara, Hitoshi ^a   Okamoto, Kazuma ^a   Ochiai, Toshiya ^a   Inoue, Jun ^b   Inazawa, Johji ^b   Otsuji, Eigo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chemotherapeutic efficacy; Esophageal squamous cell carcinoma; Glutathione S transferase P1

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; GLUTATHIONE TRANSFERASE P1; MONOCLONAL ANTIBODY; UFT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LYMPHATIC METASTASIS; MALE; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

EID: 84882673370     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2606     Document Type: Article

References (32)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. De Vita F, Di Martino N, Orditura M, Cosenza A, Galizia G, Del Genio A and Catalano G: Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study. Chest 122: 1302-1308, 2002.
3. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, Martin F, Rice DC, Sarabia AJ, Smythe WR, Vaporciyan AA, Walsh GL and Roth JA: Treatment outcomes of resected esophageal cancer. Ann Surg 236: 376-384, 2002.
4. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-1733, 2002.
5. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV and Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281: 1623-1627, 1999.
6. McKinney A, Sharp L, Macfarlane GJ and Muir CS: Oesophageal and gastric cancer in Scotland 1960-90. Br J Cancer 71: 411-415, 1995.
7. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y and Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232: 225-232, 2000.
8. Coles BF and Kadlubar FF: Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors 17: 115-130, 2003.
9. Matthias C, Jahnke V, Fryer AA and Strange RC: Influence of glutathione s-transferase and cytochrome p450 polymorphisms on prognosis of head and neck cancer. Laryngorhinootologie 81: 406-412, 2002 (In German).
10. Anderer G, Schrappe M, Brechlin AM, Lauten M, Muti P, Welte K and Stanulla M: Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 10: 715-726, 2000.
11. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC and Lenz HJ: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94: 936-942, 2002.
12. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF and Coles BF: Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 103: 810-814, 2003.
13. Lee JM, Wu MT, Lee YC, Yang SY, Chen JS, Hsu HH, Huang PM, Kuo SW, Lee CJ and Chen CJ: Association of GSTP1 polymorphism and survival for esophageal cancer. Clin Cancer Res 11: 4749-4753, 2005.
14. Wang Z, He W, Yang G, Wang J, Wang Z, Nesland JM, Holm R and Suo Z: Decreased expression of GST pi is correlated with a poor prognosis in human esophageal squamous carcinoma. BMC Cancer 10: 352, 2010.
15. Ueda Y, Shiozaki A, Itoi H, Okamoto K, Fujiwara H, Ichikawa D, Kikuchi S, Fuji N, Itoh T, Ochiai T, Komatsu S and Yamagishi H: Intraoperative pathological investigation of recurrent nerve nodal metastasis can guide the decision whether to perform cervical lymph node dissection in thoracic esophageal cancer. Oncol Rep 16: 1061-1066, 2006.
16. Shiozaki A, Yamagishi H, Itoi H, Fujiwara H, Kikuchi S, Okamoto K, Ichikawa D, Fuji N, Ochiai T, Sonoyama T and Ueda Y: Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep 13: 667-672, 2005.
17. Sobin LH, Gospodarowicz MK and Wittekind C (eds): International Union Against Cancer. TNM Classification of Malignant Tumours. 7th edition. Hoboken, NJ, Wiley-Blackwell, pp73-77, 2010.
18. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R and Kuwano H: Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 91: 1004-1009, 2004.
19. Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ and Mueller PR: Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg 86: 1131-1138, 2008.
20. Fleiss JL: Measuring nominal scale agreement among many rates. Psychol Bull 76: 378-382, 1971.
21. Nakajima T, Wang RS, Nimura Y, Pin YM, He M, Vainio H, Murayama N, Aoyama T and Iida F: Expression of cytochrome P450s and glutathione S-transferases in human esophagus with squamous-cell carcinomas. Carcinogenesis 17: 1477-1481, 1996.
22. Laborde E: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. Cell Death Differ 17: 1373-1380, 2010.
23. Rossini A, Rapozo DC, Soares Lima SC, Guimarães DP, Ferreira MA, Teixeira R, Kruel CD, Barros SG, Andreollo NA, Acatauassú R, Matos HJ, Albano RM and Pinto LF: Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population. Carcinogenesis 28: 2537-2542, 2007.
24. Li D, Dandara C and Parker MI: The 341C/T polymorphism in the GSTP1 gene is associated with increased risk of oesophageal cancer. BMC Genet 11: 47, 2010.
25. Peklak-Scott C, Smitherman PK, Townsend AJ and Morrow CS: Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther 7: 3247-3255, 2008.
26. Miyake T, Nakayama T, Naoi Y, Yamamoto N, Otani Y, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Tamaki Y and Noguchi S: GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER-negative breast cancer. Cancer Sci 103: 913-920, 2012.
27. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ and Ronai Z: Regulation of JNK signaling by GSTp. EMBO J 18: 1321-1334, 1999.
28. Sau A, Filomeni G, Pezzola S, D'Aguanno S, Tregno FP, Urbani A, Serra M, Pasello M, Picci P, Federici G and Caccuri AM: Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines. Mol Biosyst 8: 994-1006, 2012.
29. Hu Y, Ju Y, Lin D, Wang Z, Huang Y, Zhang S, Wu C and Jiao S: Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep 39: 4743-4747, 2012.
30. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ and Lee SH: Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220: 446-451, 2010.
31. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T and Yamamoto M: NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13: 864-873, 2011.
32. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, Ikeda K, Kanda T, Tsujinaka T, Nakamura K and Fukuda H: A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19: 68-74, 2012.